Simultaneous Expression of Th1- and Treg-Associated Chemokine Genes and CD4 +, CD8 +, and Foxp3 + Cells in the Premalignant Lesions of 4NQO-Induced Mouse Tongue Tumorigenesis
CXCL4 promoted the production of CD4 + CD25 + FOXP3 + treg cells in mouse sepsis model through regulating STAT5/FOXP3 pathway
Brain Foxp3+ regulatory T cells can be expanded by Interleukin-33 in mouse ischemic stroke
Regulatory T (Treg) cells are known as immune regulators to decrease infarct volume and improve outcomes after ischemic stroke. Thus, the strategies for increasing Treg cells in the ischemic brain may have beneficial effects on stroke. In this study, we aim to examine the effect of Interleukin-33 (IL-33) on Treg cell expansion in a mouse model of ischemic stroke. Mice were subjected to 30 min of middle cerebral artery occlusion (MCAO) followed by 24 h, 48 h of 72 h of reperfusion. Recombinant mouse IL-33 (2 μg) was pre-treated intracerebroventricularly at 30 min prior to MCAO. The percentage of Treg cells in the ischemic brain, related cytokines, and transcription factors, the levels of ST2 receptor, amphiregulin (AREG), and epidermal growth factor receptor (EGFR) were measured.
IL-33 treatment can increase the number of Foxp3+ Treg cells in the ischemic brain and the levels of IL-10 and TGF- β1 in serum and brain tissues at MCAO 48 h and 72 h, but not at MCAO 24 h. In the Treg cells separated from ischemic brain tissue following MCAO treated by IL-33, the expression level of the ST2 receptor was up-regulated. In addition, IL-33 may increase the mRNA level of transcription factor Foxp3. Correspondingly, IL-33 treatment also elevated the levels of AREG and EGFR at MCAO 48 h and 72 h.
We speculated that intracerebroventricular IL-33 can activate the downstream Foxp3 via ST2 receptor to increase Treg proportions in the ischemic brain. The elevated Treg cells produce AREG to activate EGFR located in neurons, which contribute to better outcomes.
Ectopic germline recombination activity of the widely-used Foxp3-YFP-Cre mouse: a case-report
Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model
CuO-Mouse Foxp3-IRES-GFP-EF1-CymR-T2A-Puro Cumate inducible lentivector plasmid | ||||
TCL500A-1 | SBI | 10ug | 1283 EUR | |
Mouse FOXP3 ELISA Kit | ||||
EMF0126 | Abclonal | 96Tests | 625.2 EUR | |
Mouse FOXP3 shRNA Plasmid | ||||
20-abx972653 | Abbexa |
|
|
|
Foxp3 Recombinant Protein (Mouse) | ||||
RP135134 | ABM | 100 ug | Ask for price | |
Foxp3 Recombinant Protein (Mouse) | ||||
RP135137 | ABM | 100 ug | Ask for price | |
Foxp3 Recombinant Protein (Mouse) | ||||
RP135140 | ABM | 100 ug | Ask for price | |
Foxp3 ORF Vector (Mouse) (pORF) | ||||
ORF045046 | ABM | 1.0 ug DNA | 607.2 EUR | |
Foxp3 ORF Vector (Mouse) (pORF) | ||||
ORF045047 | ABM | 1.0 ug DNA | 607.2 EUR | |
Foxp3 ORF Vector (Mouse) (pORF) | ||||
ORF045048 | ABM | 1.0 ug DNA | 607.2 EUR | |
FOXP3 ELISA Kit (Mouse) (OKAN05727) | ||||
OKAN05727 | Aviva Systems Biology | 96 Wells | 950.4 EUR | |
FOXP3 ELISA Kit (Mouse) (OKCD07760) | ||||
OKCD07760 | Aviva Systems Biology | 96 Wells | 981.6 EUR | |
FOXP3 ELISA Kit (Mouse) (OKEH03418) | ||||
OKEH03418 | Aviva Systems Biology | 96 Wells | 794.4 EUR | |
Anti-/ Mouse Foxp3 Antibody [3G3], PE-25ug | ||||
QAB71-PE-25ug | EnQuireBio | 25ug | 229.2 EUR | |
Foxp3 sgRNA CRISPR Lentivector set (Mouse) | ||||
K4440101 | ABM | 3 x 1.0 ug | 406.8 EUR | |
Anti-/ Mouse Foxp3 Antibody [3G3], APC-25ug | ||||
QAB71-APC-25ug | EnQuireBio | 25ug | 361.2 EUR | |
Anti-/ Mouse Foxp3 Antibody [3G3], PE-100ug | ||||
QAB71-PE-100ug | EnQuireBio | 100ug | 422.4 EUR | |
Anti-/ Mouse Foxp3 Antibody [3G3], APC-100ug | ||||
QAB71-APC-100ug | EnQuireBio | 100ug | 452.4 EUR | |
Anti-/ Mouse Foxp3 Antibody [3G3], FITC-25ug | ||||
QAB71-F-25ug | EnQuireBio | 25ug | 240 EUR |